ArticleFrontiers in cardiovascular medicine2025
Impact of ventricular pacing modalities and pacing percentage on new-onset atrial fibrillation after dual-chamber pacemaker implantation.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of the ventricular pacing modalities and ventricular pacing percentage (VP) on the incidence of new-onset atrial fibrillation (AF) following dual-chamber pacemaker implantation. We aim to explore how these factors, along with left atrial diameter (LAD), contribute to AF development, providing insights into optimizing pacemaker settings to potentially reduce AF risk in pacemaker patients. Methods: Between January 1, 2020, and December 31, 2022, a total of 371 patients who underwent initial dual-chamber pacemaker implantation at the Second Affiliated Hospital of Harbin Medical University were enrolled. These patients were categorized into two groups: the non-AF group and the AF group, based on the presence of new-onset AF during one-year follow-up. Regular remote follow-up visits were conducted postoperatively, with endpoint events defined as the detection of AF. A comparative analysis was performed to evaluate the differences in basic characteristics, implantation site of the ventricular lead, and pacemaker programming settings between the two groups. Results: The AF group exhibited a significantly higher prevalence of hypertension and a greater proportion of left bundle branch pacing (LBBP) compared to the non-AF group. Additionally, the AF group had a lower proportion of patients with ventricular pacing (VP) in the 0%-39% range, but a higher proportion of patients in the 40%-79% range. Notably, the LBBP cohort demonstrated a significantly lower incidence of AF. The AF group also presented with a larger left atrial diameter (LAD). Multivariate analysis revealed that LBBP and VP in the 0%-39% range were independently associated with a reduced risk of new-onset atrial fibrillation AF. Among the predictive indicators for new-onset AF, both LBBP and LAD demonstrated notable sensitivity and specificity. Conclusions: Ventricular pacing modalities and percentage significantly impact new-onset AF after dual-chamber pacemaker implantation. LBBP and lower VP percentages are associated with a lower risk of AF development, whereas a larger LAD may be linked to an increased likelihood of its onset. Optimizing these factors could potentially reduce the risk of AF in pacemaker patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.